Where does Zhejiang Hisun Pharmaceutical Co., Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Zhejiang Hisun Pharmaceutical Co., Ltd. ranks #5,996 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Zhejiang Hisun Pharmaceutical Co., Ltd. hold?

Zhejiang Hisun Pharmaceutical Co., Ltd. holds 57 US utility patents granted between 2015 and 2025, spanning 23 technology areas.

What is Zhejiang Hisun Pharmaceutical Co., Ltd.'s Innovation Score?

Zhejiang Hisun Pharmaceutical Co., Ltd. has an Innovation Score of 41.9 out of 100 (top 32% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Zhejiang Hisun Pharmaceutical Co., Ltd. focus on?

Zhejiang Hisun Pharmaceutical Co., Ltd.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 40 patents, ranking #463 of 6,058 assignees active in that subclass. Grants appear in 23 CPC subclasses total.

Is Zhejiang Hisun Pharmaceutical Co., Ltd.'s patent grant rate increasing or decreasing?

Zhejiang Hisun Pharmaceutical Co., Ltd.'s recent grant velocity is -68% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Zhejiang Hisun Pharmaceutical Co., Ltd.'s patents?

Zhejiang Hisun Pharmaceutical Co., Ltd.'s patents average 14.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Zhejiang Hisun Pharmaceutical Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Zhejiang Hisun Pharmaceutical Co., Ltd.

USPTO PatentsView assignee record - 57 granted patents across 23 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Zhejiang ranks #5,996 of 49,997 tracked US assignees by granted-patent volume, with 57 patents across 23 technology areas.

#5,996
of 49,997 US assignees by volume: Top 32%
by Innovation Score (41.9/100): 14.9
avg claims per patent: -68%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R5996 · Foreign Corporation #5,996 · 57 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 57 grants
UPPER-Q #5,996/49,997
PHOTO-FINISH eLux
CPC-FOCUS A61P · 23 areas
INNOV-PAR 41.9/100
CLAIMS-RICH 14.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -68% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: eLux, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Zhejiang’s 41.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 14.0 pts (33%) Velocity 2.0 pts (5%) Breadth 17.0 pts (41%) Claim depth 8.9 pts (21%)

Qualcomm Incorporated · highest

85
Apollo Endosurgery · near

42
Micware · near

42
Ultragenyx Pharmaceu… · near

42
Zhejiang Hisun… · this assignee

42
Skyhook Wireless · near

42
3D Lighting… · lowest

7

What this shows Zhejiang's Innovation Score is 41.9/100 (top 32% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Zhejiang?

Each dot is one of Zhejiang’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Zhejiang’s own 14.9 claims/patent is at or below the 18.3 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Zhejiang vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Zhejiang's grants concentrate

Zhejiang Hisun Pharmaceutical Co., Ltd. is a focused PatentsView assignee: 23 CPC subclasses with 70.2% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2019 (13 grants) versus a trough of 1 in 2024. By volume, Zhejiang sits between Vernalis (R&D) Ltd and A&D Company, Limited.

Zhejiang's three-year grant acceleration

From 2019–2021 to 2022–2024, Zhejiang Hisun Pharmaceutical Co., Ltd. moved from 20 to 6 grants (0.30x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Vernalis (R&D)

57
Visible World

57
Wargaming net

57
ZF CV Systems Glo…

57
Zymergen

57
elux

57
emomo Technology

57
Zhejiang Hisun Ph… ◀

57
A&D

56

What this shows Zhejiang holds 57 patents at rank #5,994, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Zhejiang

By rank, the assignees closest to #5,994 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Zhejiang's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Zhejiang, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Zhejiang ranks #463 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (42 here).

Apollo Endosurgery, Inc. 42 Micware Co., Ltd. 42 Ultragenyx Pharmaceutical Inc. 42 Skyhook Wireless, Inc. 42

Similar claim depth

Nearest assignees by average claims per patent (14.9 here).

Schreder S.A. 14.9 avg University of South Florida 14.9 avg Purdue Research Foundation 14.9 avg Advansix Resins & Chemicals LLC 14.9 avg

Zhejiang's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 32% higher than 68% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Zhejiang Hisun Pharmaceutical Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	3.5%
2016	7	12.3%
2017	11	19.3%
2018	8	14.0%
2019	13	22.8%
2020	5	8.8%
2021	2	3.5%
2022	3	5.3%
2023	2	3.5%
2024	1	1.8%
2025partial year	3	5.3%

Which technologies does Zhejiang Hisun Pharmaceutical Co., Ltd. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 40

C07D - Heterocyclic Compounds 36

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 26

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 9

C07C - Acyclic OR Carbocyclic Compounds 9

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 9

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 8

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 7

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 5

C12R - Indexing Scheme Associated With Subclasses C12c - C12q, Relating TO Microorganisms 5

C12Y - Enzymes 3

A23L - Foods, Foodstuffs OR Non-alcoholic Beverages, NOT Otherwise Provided FOR; Preparation OR Treatment Thereof 2

B01D - Separation 2

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 2

C07J - Steroids 2

Top 15 of 23 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Zhejiang Hisun Pharmaceutical Co., Ltd.'s patent record in context - here's where to go next.

Zhejiang Hisun Pharmaceutical Co., Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 70.2% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #5,996 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Zhejiang Hisun Pharmaceutical Co., Ltd. against Vernalis (R&D) Ltd, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 41.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.